Our finding of obestatin’s stimulatory effect on insulin combined with the other beneficial effects of obestatin on β-cells, makes obestatin an extremely attractive multifunctional therapeutic candidate for Type 2 diabetes. Here, GHRL is linked to type 2 diabetes mellitus.